Portal de Periódicos da CAPES

Is OCT Angiography Useful in Neurodegenerative Diseases?

2019; Volume: 50; Issue: 5 Linguagem: Inglês

10.3928/23258160-20190503-02

2325-8179

Dilraj S. Grewal, Sharon Fekrat, Howard F. Fine,

Peripheral Artery Disease Management

Practical RetinaIs OCT Angiography Useful in Neurodegenerative Diseases? Dilraj S. Grewal, MD, , , MD Sharon Fekrat, MD, , and , MD Howard F. Fine, Dilraj S. Grewal, MD , Sharon Fekrat, MD , and Howard F. Fine Published Online:May 03, 2019https://doi.org/10.3928/23258160-20190503-02Cited by:4PDFView Full Text ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInRedditEmail SectionsMore1.Fraser L. Estimation of future cases of dementia from those born in 2015. http://cdn.dementiablog.org/wp-content/uploads/2015/09/OHE_Consulting_ARUK_FINAL.pdf. Published July 17, 2015. Accessed September 23, 2018. Google Scholar2.Sadun AA, Bassi CJ. Optic nerve damage in Alzheimer's disease. Ophthalmology. 1990; 97(1):9–17.10.1016/S0161-6420(90)32621-0 Crossref MedlineGoogle Scholar3.Knoll B, Simonett J, Volpe NJ, et al.Retinal nerve fiber layer thickness in amnestic mild cognitive impairment: Case-control study and meta-analysis. Alzheimers Dement (Amst). 2016; 4:85–93. Crossref MedlineGoogle Scholar4.Bulut M, Yaman A, Erol MK, et al.Choroidal thickness in patients with mild cognitive impairment and Alzheimer's type dementia. J Ophthalmol. 2016; 2016:7291257. MedlineGoogle Scholar5.Bulut M, Kurtulus F, Gozkaya O, et al.Evaluation of optical coherence tomography angiographic findings in Alzheimer's type dementia. Br J Ophthalmol. 2018; 102(2):233–237.10.1136/bjophthalmol-2017-310476 Crossref MedlineGoogle Scholar6.Kwapong WR, Ye H, Peng C, et al.Retinal microvascular impairment in the early stages of Parkinson's disease. Invest Ophthalmol Vis Sci. 2018; 59(10):4115–4122.10.1167/iovs.17-23230 Crossref MedlineGoogle Scholar7.Yoon S, Grewal D, Polascik B, et al.Comparison of retinal microvasculature and neurodegenerative changes among Alzheimer's disease, mild cognitive impairment, and controls. Invest Ophthalmol Vis Sci. 2018; 59(9):2818–2818. MedlineGoogle Scholar8.Di Marco LY, Venneri A, Farkas E, Evans PC, Marzo A, Frangi AF. Vascular dysfunction in the pathogenesis of Alzheimer's disease – A review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol Dis. 2015; 82:593–606.10.1016/j.nbd.2015.08.014 Crossref MedlineGoogle Scholar9.Caroli A, Testa C, Geroldi C, et al.Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment. J Neurol. 2007; 254(12):1698–1707.10.1007/s00415-007-0631-7 Crossref MedlineGoogle Scholar10.Koronyo Y, Biggs D, Barron E, et al.Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease. JCI Insight. 2017; 2(16). pii: 93621. doi: . eCollection 2017 Aug 17.10.1172/jci.insight.93621 Crossref MedlineGoogle Scholar11.Koronyo Y, Salumbides BC, Black KL, Koronyo-Hamaoui M. Alzheimer's disease in the retina: Imaging retinal abeta plaques for early diagnosis and therapy assessment. Neurodegener Dis. 2012; 10(1–4):285–293.10.1159/000335154 Crossref MedlineGoogle Scholar12.Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, et al.Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage. 2011; 54Suppl 1:S204–217.10.1016/j.neuroimage.2010.06.020 Crossref MedlineGoogle Scholar13.O'Bryhim B, Apte RS, Kung N, Coble D, Van Stavern GP. Association of preclinical Alzheimer disease with optical coherence tomographic angiography findings. JAMA Ophthalmology. 2018.10.1001/jamaophthalmol.2018.3556 Crossref MedlineGoogle Scholar14.Curcio CA. Viewing retinal vasculature in alzheimer disease. JAMA Ophthalmology. 2018; 136(11):1242–1248.10.1001/jamaophthalmol.2018.3569 Crossref MedlineGoogle Scholar15.Song IU, Lee JE, Kwon DY, Park JH, Ma HI. Parkinson's disease might increase the risk of cerebral ischemic lesions. Int J Med Sci. 2017; 14(4):319–322.10.7150/ijms.18025 Crossref MedlineGoogle Scholar16.Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging. 2000; 21(2):321–330.10.1016/S0197-4580(00)00125-1 Crossref MedlineGoogle Scholar17.Ong YT, Hilal S, Cheung CY, et al.Retinal neurodegeneration on optical coherence tomography and cerebral atrophy. Neurosci Lett. 2015; 584:12–16.10.1016/j.neulet.2014.10.010 Crossref MedlineGoogle Scholar18.Casaletto KB, Ward ME, Baker NS, et al.Retinal thinning is uniquely associated with medial temporal lobe atrophy in neurologically normal older adults. Neurobiol Aging. 2017; 51:141–147.10.1016/j.neurobiolaging.2016.12.011 Crossref MedlineGoogle Scholar19.den Haan J, Verbraak FD, Visser PJ, Bouwman FH. Retinal thickness in Alzheimer's disease: A systematic review and meta-analysis. Alzheimers Dement (Amst). 2017; 6:162–170. Crossref MedlineGoogle Scholar20.Lommatzsch C, Rothaus K, Koch JM, Heinz C, Grisanti S. OCTA vessel density changes in the macular zone in glaucomatous eyes. Graefes Arch Clin Exp Ophthalmol. 2018; 256(8):1499–1508.10.1007/s00417-018-3965-1 Crossref MedlineGoogle Scholar21.Cheung CY, Ong YT, Ikram MK, et al.Microvascular network alterations in the retina of patients with Alzheimer's disease. Alzheimers Dement. 2014; 10(2):135–142.10.1016/j.jalz.2013.06.009 Crossref MedlineGoogle Scholar22.Munk MR, Giannakaki-Zimmermann H, Berger L, et al.OCT-angiography: A qualitative and quantitative comparison of 4 OCT-A devices. PLoS One. 2017; 12(5):e0177059.10.1371/journal.pone.0177059 Crossref MedlineGoogle Scholar23.Rabiolo A, Gelormini F, Marchese A, et al.Macular perfusion parameters in different angiocube sizes: Does the size matter in quantitative optical coherence tomography angiography?Invest Ophthalmol Vis Sci. 2018; 59(1):231–237.10.1167/iovs.17-22359 Crossref MedlineGoogle Scholar24.Dong J, Jia YD, Wu Q, et al.Interchangeability and reliability of macular perfusion parameter measurements using optical coherence tomography angiography. Br J Ophthalmol. 2017; 101(11):1542–1549.10.1136/bjophthalmol-2016-309441 Crossref MedlineGoogle Scholar25.Jiang H, Wei Y, Shi Y, et al.Altered macular microvasculature in mild cognitive impairment and Alzheimer disease. J Neuroophthalmol. 2018; 38(3):292–298.10.1097/WNO.0000000000000580 Crossref MedlineGoogle Scholar Previous article Next article FiguresReferencesRelatedDetailsCited by Abraham A, Guo X, Arsiwala L, Dong Y, Sharrett A, Huang D, You Q, Liu L, Lujan B, Tomlinson A, Mosley T, Coresh J, Jia Y, Mihailovic A and Ramulu P (2021) Cognitive decline in older adults: What can we learn from optical coherence tomography ( OCT )‐based retinal vascular imaging? , Journal of the American Geriatrics Society, 10.1111/jgs.17272, 69:9, (2524-2535), Online publication date: 1-Sep-2021. Subramanian M, Vig V, Chung J, Fiorello M, Xia W, Zetterberg H, Blennow K, Zetterberg M, Shareef F, Siegel N, Ness S, Jun G and Stein T (2020) Neurofilament light chain in the vitreous humor of the eye, Alzheimer's Research & Therapy, 10.1186/s13195-020-00677-4, 12:1, Online publication date: 1-Dec-2020. Koman-Wierdak E, Róg J, Brzozowska A, Toro M, Bonfiglio V, Załuska-Ogryzek K, Karakuła-Juchnowicz H, Rejdak R and Nowomiejska K (2021) Analysis of the Peripapillary and Macular Regions Using OCT Angiography in Patients with Schizophrenia and Bipolar Disorder, Journal of Clinical Medicine, 10.3390/jcm10184131, 10:18, (4131) Tsokolas G, Tsaousis K, Diakonis V, Matsou A and Tyradellis S (2020) Optical Coherence Tomography Angiography in Neurodegenerative Diseases: A Review, Eye and Brain, 10.2147/EB.S193026, Volume 12, (73-87) Request Permissions InformationCopyright 2019, SLACK IncorporatedPDF downloadDilraj S. Grewal, MD, can be reached at Duke Eye Center, 2351 Erwin Road, Box 3802, Durham, NC 27710; email: dilraj.[email protected]edu.Howard F. Fine, MD, MHSc, can be reached at Rutgers Robert Wood Johnson Medical School; New Jersey Retina, 10 Plum Street, Suite 600, New Brunswick, NJ 08901; email: [email protected]com.Sharon Fekrat, MD, can be reached at Duke Eye Center, 2351 Erwin Road, Box 3802, Durham, NC 27710; email: sharon.[email protected]edu.Disclosures: Dr. Grewal has received personal fees from Allergan and Alimera outside the submitted work. Dr. Fine is a consultant and/or speaker for Alimera, Allergan, Genentech, Regeneron, and Spark Therapeutics and has equity/patent interests in Auris Surgical Robotics. Dr. Fekrat reports no relevant financial disclosures.This work was supported in part by funding from the National Institutes of Health P30EY005722 to Duke University and the 2018 Unrestricted Grant from Research to Prevent Blindness (Duke University).